Literature DB >> 22198520

Positive lymph nodes do not metastasize.

Jutta Engel1, Rebecca T Emeny, Dieter Hölzel.   

Abstract

Our understanding of the role of lymph nodes (LN) in the metastasization process (MET) is marginal. Positive LNs (pLN) are the most important prognostic factor and lymph node dissection (LND) is still standard practice in primary treatment. However, up to now, there is almost no evidence that elective LND has a survival benefit. Based on many clinical and experimental findings, we propose that tumor foci in regional LN are incapable of metastasization and can therefore not infiltrate further LN and organs. Available data demonstrate a very early infiltration of MET capable tumor cells from the primary tumor into regional LN, and thereafter an increased probability of subsequent LN infiltrations. Disparate growth rates of the first versus subsequent infiltrating tumors as well as the asymptotic growth and prognosis of large tumor foci in LN explain many clinical observations for solid tumors. The consequence of the hypothesis "pLN do not metastasize" would impact clinical treatment and research and contribute to understanding the mounting evidence against LND.

Entities:  

Mesh:

Year:  2012        PMID: 22198520     DOI: 10.1007/s10555-011-9343-7

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  23 in total

Review 1.  [Cervical, inguinal and abdominal lymphnode dissection].

Authors:  T W Kraus; K Suna; S Berkhoff; E Jäger; U Kraus-Tiefenbacher
Journal:  Chirurg       Date:  2013-07       Impact factor: 0.955

Review 2.  Sentinel node biopsy and axillary dissection in breast cancer: the evidence and its limits.

Authors:  Wolfgang Janni; Thorsten Kühn; Lukas Schwentner; Rolf Kreienberg; Tanja Fehm; Achim Wöckel
Journal:  Dtsch Arztebl Int       Date:  2014-04-04       Impact factor: 5.594

3.  How nescience may obscure evidence.

Authors:  M-L Sautter-Bihl; F Sedlmayer; W Budach; J Dunst; P Feyer; R Fietkau; W Haase; W Harms; M D Piroth; R Souchon; F Wenz; R Sauer
Journal:  Strahlenther Onkol       Date:  2014-10       Impact factor: 3.621

Review 4.  [Clinical and epidemiological cancer registration in Germany].

Authors:  D Hölzel; G Schubert-Fritschle; M Schmidt; R Eckel; J Engel
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

Review 5.  Is Axillary Sentinel Lymph Node Biopsy Required in Patients Who Undergo Primary Breast Surgery?

Authors:  Toralf Reimer; Jutta Engel; Marcus Schmidt; Birgitte Vrou Offersen; Marjolein L Smidt; Oreste David Gentilini
Journal:  Breast Care (Basel)       Date:  2018-08-24       Impact factor: 2.860

Review 6.  What Is the Best Management of cN0pN1(sn) Breast Cancer Patients?

Authors:  Jana de Boniface; Marcus Schmidt; Jutta Engel; Marjolein L Smidt; Birgitte Vrou Offersen; Toralf Reimer
Journal:  Breast Care (Basel)       Date:  2018-09-05       Impact factor: 2.860

7.  Origins of lymphatic and distant metastases in human colorectal cancer.

Authors:  Kamila Naxerova; Johannes G Reiter; Elena Brachtel; Jochen K Lennerz; Marc van de Wetering; Andrew Rowan; Tianxi Cai; Hans Clevers; Charles Swanton; Martin A Nowak; Stephen J Elledge; Rakesh K Jain
Journal:  Science       Date:  2017-07-07       Impact factor: 47.728

8.  Selection and adaptation during metastatic cancer progression.

Authors:  Christoph A Klein
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

9.  Personalized axillary dissection: the number of excised lymph nodes of nodal-positive breast cancer patients has no significant impact on relapse-free and overall survival.

Authors:  Florian Ebner; Achim Wöckel; Wolfgang Janni; Rolf Kreienberg; Lukas Schwentner; Manfred Wischnewsky
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-24       Impact factor: 4.553

10.  Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes.

Authors:  Ikram Ullah; Govindasamy-Muralidharan Karthik; Amjad Alkodsi; Una Kjällquist; Gustav Stålhammar; John Lövrot; Nelson-Fuentes Martinez; Jens Lagergren; Sampsa Hautaniemi; Johan Hartman; Jonas Bergh
Journal:  J Clin Invest       Date:  2018-02-26       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.